

**Natco Pharma Limited**

Regd. Off: NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad-500 033, INDIA.
Tel: +91 40 23547532, Fax: +91 40 23548243

25th June, 2012

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith press release for your perusal

Thanking you

Yours faithfully
For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

M Adinarayana
Company Secretary &
G.M. (Leal & Corp. Affairs)

Encl: as above.



Natco Pharma Limited

Regd. Off : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

June 25, 2012

NATCO – Update on generic Copaxone ®

In a ruling delivered on 22nd June, 2012, the US District Court for the Southern District of New York has upheld the contention of Teva Pharmaceuticals (Teva) that **NATCO** Pharma's (the Company) abbreviated new drug application (ANDA) for the generic version of Copaxone ® infringes all the asserted claims of Teva Pharmaceuticals.

NATCO has filed, with its partner Mylan Inc., in June 2008, an ANDA seeking approval for marketing of the generic version of the relapsing, remitting multiple sclerosis drug Copaxone ® and obtained a Para IV certification which essentially challenges the existing patents held by Teva Pharmaceuticals.

NATCO is disappointed in the Court's decision. While the Company has not yet had the opportunity to review the Court's opinion, it will fully investigate all available options for appeal once the Court's full opinion becomes available.

Forwarded for favor of publication

For NATCO PHARMA LIMITED

M. Adinarayana
M. ADINARAYANA
Company Secretary & G.M.
(Legal & Corporate Affairs)